Last reviewed · How we verify
therapeutic testosterone
Therapeutic testosterone replaces or supplements endogenous testosterone to restore normal hormonal levels and physiological function.
Therapeutic testosterone replaces or supplements endogenous testosterone to restore normal hormonal levels and physiological function. Used for Testosterone deficiency (hypogonadism), Potential supportive care in cancer patients with low testosterone.
At a glance
| Generic name | therapeutic testosterone |
|---|---|
| Also known as | Mertestate, Testoderm, Testolin, Testosterone, Testostroval |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Androgen replacement therapy |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Testosterone is an androgenic steroid hormone that binds to androgen receptors throughout the body, promoting development and maintenance of male sexual characteristics, muscle mass, bone density, and metabolic function. In therapeutic contexts, exogenous testosterone is used to treat testosterone deficiency (hypogonadism) and restore normal endocrine function. The drug may also have immunomodulatory effects relevant to cancer treatment contexts, though this application is less common.
Approved indications
- Testosterone deficiency (hypogonadism)
- Potential supportive care in cancer patients with low testosterone
Common side effects
- Polycythemia (elevated red blood cell count)
- Gynecomastia (breast tissue enlargement)
- Acne
- Mood changes / aggression
- Fluid retention / edema
- Liver enzyme elevation
Key clinical trials
- Oxandrolone Multiligament Knee (PHASE4)
- Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy (PHASE2)
- Acute Vitamin D Supplementation on Testosterone in Females (NA)
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer (NA)
- Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension
- Body Composition Assessment in Transgender Population.
- PREDICTORS OF TESTOSTERONE DECLINE IN MIDDLE-AGED MEN
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |